Premium
Tubal patency after clinical treatment of unruptured ectopic pregnancy
Author(s) -
Elito J.,
Han K.K.,
Camano L.
Publication year - 2005
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2004.12.018
Subject(s) - medicine , hysterosalpingography , methotrexate , ectopic pregnancy , fallopian tube , pregnancy , obstetrics , gynecology , surgery , infertility , biology , genetics
Objective To evaluate tubal patency using hysterosalpingography after clinical treatment of tubal pregnancy. Method Of 80 patients who underwent hysterosalpingography after clinical treatment of tubal pregnancy from April 1994 to February 2002, 30 were treated with a single 50 mg/m 2 dose of methotrexate intramuscularly ( n =30) and 50 were followed up expectantly. Results Patency of the ipsilateral tube was 84% after methotrexate treatment and 78% after expectant management. In addition, contralateral tubal patency was 97% after methotrexate treatment and 92% after expectant management. There were no statistically significant differences between the groups. Conclusion Findings from this study suggest similar tubal patency rates after methotrexate treatment and expectant management.